---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-23-000024"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T23:49:09.563988+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ligand Q1 revenue $44M beats prior year; raises FY2023 EPS guidance to $4.60-$4.75

## Summary
- Total revenue $44.0M, up 21% from $36.5M in Q1 2022; net income $43.6M vs loss $12.9M.
- Raised FY2023 guidance: royalties $78-82M (prev $74-78M); diluted EPS $4.60-4.75 (prev $3.30-3.45).
- Royalty revenue $17.2M (+28% YoY) driven by Kyprolis and Pelican platform; core Captisol sales $10.6M (+71%).
- Sold 3.2M shares of Viking Therapeutics for $43M net proceeds; holds 3.6M VKTX shares as of Mar 31, 2023.
- Travere's FILSPARI approved for IgA nephropathy in Feb; Phase 3 FSGS study missed primary endpoint.

## SEC filing metadata
- accession: 0000886163-23-000024
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616323000024/0000886163-23-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616323000024/lgnd-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-23-000024
- JSON: https://secwatch.observer/filing/0000886163-23-000024.json
- Plain text: https://secwatch.observer/filing/0000886163-23-000024.txt

## Key facts
- Earnings Releases
  LIGAND PHARMACEUTICALS INC reported the three months ended March 31, 2023 results: revenue $44.0 million, net income $43.6 million, or $2.43 per diluted share. Guidance raised.
  - Period: the three months ended March 31, 2023
  - Revenue: $44.0 million
  - Net income: $43.6 million, or $2.43 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. “2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616323000024/0000886163-23-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.